From the Guidelines
The ideal treatment indication for Cefoperazone/Sulbactam is for infections caused by Pseudomonas aeruginosa and other gram-negative bacteria, including Enterobacteriaceae.
- The recommended dose is 4 g IV q12h 1.
- The duration of treatment typically ranges from 7-14 days, depending on the severity and type of infection.
- Cefoperazone/Sulbactam is often used in combination with other antibiotics, such as aminoglycosides, to enhance its effectiveness against certain types of bacteria 1.
- It is essential to note that the use of Cefoperazone/Sulbactam should be guided by antibiotic susceptibility testing to ensure its effectiveness against the specific bacteria causing the infection 1.
- In cases of complicated intra-abdominal infections or skin and soft tissue infections, Cefoperazone/Sulbactam may be used as part of a broader antibiotic regimen, including other agents such as metronidazole or vancomycin 1.
- The choice of antibiotic regimen should be based on the severity of the infection, the type of bacteria involved, and the patient's underlying medical conditions 1.
From the Research
Ideal Treatment Indication for Cefoperazone/Sulbactam
The ideal treatment indication for Cefoperazone/Sulbactam can be determined based on the following factors:
- Type of infection: Cefoperazone/Sulbactam is effective against various types of infections, including hospital-acquired pneumonia (HAP), healthcare-associated pneumonia (HCAP), and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections 2, 3.
- Minimum inhibitory concentration (MIC): The clinical success rate of Cefoperazone/Sulbactam is high when the MIC is ≤32/32 mg/L 3, 4.
- Patient population: Cefoperazone/Sulbactam can be used in pediatric patients with sepsis, as well as in critically ill adults with thrombotic thrombocytopenic purpura (TTP) undergoing therapeutic plasma exchange 5, 6.
Key Considerations
Some key considerations for the ideal treatment indication of Cefoperazone/Sulbactam include:
- Dosage: The usual dosing regimen of 2 g every 12 hours may be suitable for patients with HAP and HCAP 2.
- Combination therapy: Cefoperazone/Sulbactam can be effective in combination with other antibiotics, but its use as monotherapy may also be beneficial in certain cases 2, 3.
- Monitoring: Plasma concentration monitoring is advised when Cefoperazone/Sulbactam is administered during therapeutic plasma exchange 6.
Clinical Outcomes
The clinical outcomes of Cefoperazone/Sulbactam treatment can be influenced by various factors, including:
- MIC values: High MIC values (≥64 mg/L) are associated with a higher risk of mortality 4.
- Comorbidities: Patients with comorbidities, such as heart failure and malignancy, may have a higher risk of poor outcomes 3, 4.
- Disease severity: High Sequential Organ Failure Assessment (SOFA) scores are associated with increased 30-day mortality 3.